Clinical Trials · NCT02903368
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 118
- Start date
- Oct 2016
- Locations
- 4 sites, United States
- Primary endpoint
- Combined pCR or MRD Rate [Part 1]